Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b4ee13af463c18c765406625e1c5d44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2b94e8ed234ad484c5475ddd7b91302f |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5258 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2795-18123 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-52 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-085 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-085 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
filingDate |
2017-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2020-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3aba605ea609f6e0dcfe92747311a98 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c27f1fa656dbfa102e4c1b6f7c9ceb84 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7826d46224f6e03f719454897263cf7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cdfd907cac9b2d82a1d50e479cc586d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce8e073bfdd5889f18da36515337e759 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_768f3d85096740ac9b874789b8cc6042 |
publicationDate |
2020-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-10821167-B2 |
titleOfInvention |
VLP-based vaccines for targeting Staphylococcus aureus secreted virulence factors |
abstract |
The present invention is directed to virus-like particles (VLPs) which are engineered to present epitopes from Staphylococcus aureus (SA), preferably autoinducing peptides (AIPs) which regulate quorum-sensing dependent virulence in this pathogen, or epitopes from SA toxins and leukocidins. These VLPs may be used to provide immunogenic compositions and efficacious vaccines. In a mouse model of SA dermonecrosis, vaccination with AIP-containing VLPs or SA toxin-containing VLPs induces protective immunity to limit the pathogenesis of SA infection and promote bacterial clearance. |
priorityDate |
2016-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |